Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad

被引：75

作者：

Matsubara, Daisuke ^{[1
,2
]}

Kanai, Yoshihiko ^{[3
]}

Ishikawa, Shumpei ^{[4
]}

Ohara, Shiori ^{[1
]}

Yoshimoto, Taichiro ^{[1
]}

Sakatani, Takashi ^{[1
]}

Oguni, Sachiko ^{[1
]}

Tamura, Tomoko ^{[1
]}

Kataoka, Hiroaki ^{[5
]}

Endo, Shunsuke ^{[3
]}

Murakami, Yoshinori ^{[2
]}

Aburatani, Hiroyuki ^{[6
]}

Fukayama, Masashi ^{[4
]}

Niki, Toshiro ^{[1
]}

机构：

[1] Jichi Med Univ, Div Integrat Pathol, Dept Pathol, Shimotsuke, Tochigi 3290498, Japan

[2] Univ Tokyo, Inst Med Sci, Div Mol Pathol, Dept Canc Biol,Minato Ku, Tokyo, Japan

[3] Jichi Med Univ, Div Gen Thorac Surg, Dept Surg, Shimotsuke, Tochigi 3290498, Japan

[4] Univ Tokyo, Grad Sch Med, Dept Human Pathol, Bunkyo Ku, Tokyo, Japan

[5] Miyazaki Univ, Fac Med, Dept Pathol, Miyazaki, Japan

[6] Univ Tokyo, Res Ctr Adv Sci & Technol, Div Genome Sci, Lab Syst Biol & Med,Meguro Ku, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 12期

关键词：

RET fusion; Lung adenocarcinoma; Cell line; Vandetanib; GROWTH-FACTOR-RECEPTOR; RET GENE FUSION; CANCER; ALK; INHIBITOR; GENOME; ROS1;

D O I：

10.1097/JTO.0b013e3182721ed1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rearranged during transfection (RET) fusions have been newly identified in approximately 1% of patients with primary lung tumors. However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied. In this study, we report identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line LC-2/ad. LC-2/ad showed distinctive sensitivity to the RET inhibitor, vandetanib, among 39 non-small lung cancer cell lines. The xenograft tumor of LC-2/ad showed cribriform acinar structures, a morphologic feature of primary RET fusion-positive lung adenocarcinomas. LC-2/ad cells could provide useful resources to analyze molecular functions of RET-fusion protein and its response to RET inhibitors.

引用

页码：1872 / 1876

页数：5

共 50 条

[1] Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo
Suzuki, Makito
Makinoshima, Hideki
Matsumoto, Shingo
Suzuki, Ayako
Mimaki, Sachiyo
Matsushima, Koutatsu
Yoh, Kiyotaka
Goto, Koichi
Suzuki, Yutaka
Ishii, Genichiro
Ochiai, Atsushi
Tsuta, Koji
Shibata, Tatsuhiro
Kohno, Takashi
Esumi, Hiroyasu
Tsuchihara, Katsuya
CANCER SCIENCE, 2013, 104 (07) : 896 - 903
[2] ESTABLISHMENT AND CHARACTERIZATION OF A HUMAN LUNG ADENOCARCINOMA CELL-LINE (LC-2/AD) PRODUCING ALPHA(1)-ANTITRYPSIN IN-VITRO
KATAOKA, H
ITOH, H
SEGUCHI, K
KOONO, M
ACTA PATHOLOGICA JAPONICA, 1993, 43 (10): : 566 - 573
[3] Acquired Resistance to Osimertinib by CCDC6-RET Fusion in a Patient with EGFR T790M Mutant Metastatic Lung Adenocarcinoma
Iams, W.
Chae, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2249 - S2250
[4] Use of Cabozantinib in a Patient With EGFR-Mutated Non-Small-Cell Lung Cancer Harboring Acquired CCDC6-RET Fusion
Chae, Young Kwang
Viveiros, Pedro
Heleno, Caio T.
Bilal, Haris
Sukhadia, Bhoomika A.
Oh, Michael S.
Sheikh, Muhamad Mubbashir
Iams, Wade T.
Park, Lee Chun
JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 5
[5] Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion
Liu, Cheng-Yin
Liu, Chia-Hsin
ONCOTARGETS AND THERAPY, 2024, 17 : 499 - 506
[6] CCDC6-RET fusion protein regulates Ras/MAPK signaling through the fusion-GRB2-SHC1 signal niche
Qiu, Ting
Kong, Yichao
Wei, Guifeng
Sun, Kai
Wang, Ruijie
Wang, Yang
Chen, Yiji
Wang, Wenxin
Zhang, Yun
Jiang, Caihong
Yang, Peiguo
Xie, Tian
Chen, Xiabin
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (23)
[7] Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
Meng, Yan
Li, Lulu
Wang, Huan
Chen, Xiaofang
Yue, Yali
Wang, Meiqing
Meng, Lingru
Li, Bafei
Li, Xiao
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (08)
[8] A NOVEL HUMAN LUNG ADENOCARCINOMA CELL-LINE (LC89)
PAGANUZZI, M
MARRONI, P
ZANNINI, C
PEZZOLO, A
GIMELLI, G
CAVALLO, F
VERZOLA, D
DEANGELIS, P
FORNI, G
GROSSI, CE
CANCER DETECTION AND PREVENTION, 1993, 17 (02): : 343 - 343
[9] A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1+ lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations
Nakasuka, Takamasa
Ohashi, Kadoaki
Watanabe, Hiromi
Kubo, Toshio
Matsumoto, Shingo
Goto, Koichi
Hotta, Katsuyuki
Maeda, Yoshinobu
Kiura, Katsuyuki
LUNG CANCER, 2021, 156 : 1 - 4
[10] GENOTYPIC, PHENOTYPIC AND BIOLOGICAL CHARACTERIZATION OF A NOVEL HUMAN LUNG ADENOCARCINOMA CELL-LINE (LC-89)
PAGANUZZI, M
MARRONI, P
PEZZOLO, A
GIMELLI, G
CAVALLO, F
DIPIERRO, F
DEANGELIS, P
FORNI, G
GROSSI, CE
ONCOLOGY, 1994, 51 (03) : 220 - 225

← 1 2 3 4 5 →